Apitegromab is an example of muscle-directed research reaching a specific clinical setting. As of this review, describing it only as an experimental SMA drug is outdated: the US Food and Drug Administration approved apitegromab-mstn, branded Isembyld, on 11 September 2026. That is a defined regulatory milestone, not approval for general muscle gain. FDA biological-product record.
A muscle target alongside an existing SMA treatment
Apitegromab inhibits the activation of myostatin by binding its precursor forms. That differs from blocking the activin receptors used by several ligands. Its early human study examined safety, pharmacokinetics and target engagement in healthy volunteers. Such a study can show that a drug reaches and affects its intended pathway; it is not a trial of sporting performance or a demonstration of long-term benefit in healthy people. Randomised phase 1 study, 2021.
In SMA, the central question was whether addressing muscle could add to treatment directed at survival motor neuron biology. The current US label covers adults and children aged two years and older who are receiving SMN2-targeted therapy. That qualification is part of the indication, not a detail that can be removed when summarising the evidence. US approval also does not establish Australian registration or availability. FDA prescribing information, September 2026.
What SAPPHIRE actually compared
SAPPHIRE enrolled 188 people aged 2–21 years with nonambulatory type 2 or type 3 SMA who were receiving nusinersen or risdiplam. The primary efficacy population was the 156 participants aged 2–12. After 12 months, the combined apitegromab groups differed from placebo by 1.8 points on the Hammersmith Functional Motor Scale-Expanded, with a 95% confidence interval of 0.30–3.32. The reported group changes were 0.6 and −1.2 points, respectively. SAPPHIRE peer-reviewed report, 2025.
That is a between-group motor-function result. It is not a percentage increase in muscle, and it does not mean every participant improved by the same amount. The higher-dose arm’s separate comparison did not reach statistical significance. The paper reported similar overall adverse-event patterns between groups and no discontinuations due to adverse events. Those findings should be read alongside the later regulatory safety assessment, rather than used as a blanket statement that the drug has no risks. SAPPHIRE outcomes and limitations.
How the earlier studies fit
The phase 2 TOPAZ study provided the earlier clinical signal. Its cohorts differed in age, ambulatory status and background treatment, and it did not supply the same placebo-controlled comparison as SAPPHIRE. The publication describes an active-treatment study, including a blinded comparison between two apitegromab exposures in one cohort. Improvements within such a study can be informative, but they cannot independently separate all treatment effects from differences between participants or changes over time. TOPAZ primary report, 2024.
A 36-month TOPAZ follow-up added information about sustained observations and patient-reported outcomes. Longer follow-up is valuable for a chronic condition, but an extension retains important limitations: continued participants are a selected group, and an open-label extension does not become a new blinded placebo comparison. It is best used to complement, not replace, the pivotal trial. TOPAZ long-term follow-up, 2024.
The current safety context includes fractures
The FDA label warns that fractures, including serious fractures, have occurred and that Isembyld may increase fracture risk. It describes particular concern in people with low bone density or a history of fractures. This is a more complete picture than repeating an earlier announcement that treatment was generally well tolerated. A manageable risk in a defined clinical population is still a real risk; approval does not erase it. FDA warnings and adverse-reaction sections.
Why this cannot become a healthy-adult performance claim
SMA has a specific disease mechanism, baseline functional limitations and background treatment. A result on an SMA motor scale does not establish an improvement in athletic strength, endurance or recovery. Even the existence of a healthy-volunteer safety study does not fill that gap: its purpose and endpoints were different. The right question is whether the claim being made was actually tested in the population being discussed.
A separate obesity programme
There is also separate obesity research. A randomised phase 2 apitegromab study with tirzepatide was published in 2026, but that concerns body composition during medically studied weight loss, not performance enhancement in healthy adults. It is another research question requiring its own interpretation. Obesity phase 2 publication, 2026.
SAPPHIRE is meaningful because it tests a functional outcome in a carefully specified setting. Preserving that specificity makes the science more useful.
Continue with How to read a clinical trial for a closer look at interpreting research evidence.
Sources and further reading
- Isembyld FDA approval record — FDA regulatory record; 2026-09-11.
- Isembyld prescribing information — FDA approved label; 2026-09.
- Apitegromab phase 1 safety and target engagement — Peer-reviewed randomised phase 1 trial; 2021-05-08.
- SAPPHIRE phase 3 trial — Peer-reviewed randomised phase 3 trial; 2025-09.
- TOPAZ primary trial report — Peer-reviewed phase 2 study; 2024-02-08.
- TOPAZ 36-month follow-up — Peer-reviewed extension study; 2024-07-22.
- Apitegromab with tirzepatide in obesity — Peer-reviewed randomised phase 2 trial; 2026-06-08.
